# T-Cypher Bio

> T-Cypher Bio is an Oxford, UK biotechnology company building a pipeline of TCR (T cell receptor) therapeutics for solid tumours and immune-mediated diseases. Spun out of Orbit Discovery in 2021 on technology licensed from the University of Oxford, it pairs a high-throughput, functional bead-display platform with immunopeptidomics, AI and bioinformatics to deconvolute vast T cell repertoires, find disease-specific targets, and identify potent, target-specific TCRs.

- **Founded:** 2021
- **Headquarters:** Oxford, United Kingdom
- **Founders:** Thomas Lars Andresen (Founding CEO / Non-Executive Director), Graham Ogg (Co-founder & Chair of Scientific Advisory Board)
- **Team size:** ~43 employees
- **Products:** D-Cypher platform, Bead-display screening, T-Synapse, T-Ca (T-Cα), TCR therapeutics pipeline
- **Notable:** Spun out of Orbit Discovery in 2021 as a standalone TCR therapeutics company., Built the D-Cypher integrated platform to overcome long-standing TCR discovery bottlenecks., Developed a functional bead-display approach that avoids T cell cloning and soluble-TCR generation.

## Products & services

- **D-Cypher platform** — Integrated, high-throughput functional platform that overcomes core challenges in TCR discovery by selecting therapeutically relevant targets and identifying potent, target-specific TCRs.
- **Bead-display screening** — Microfluidic bead-display technology that screens TCR function directly from patient T cells - no T cell cloning or soluble-TCR generation required.
- **T-Synapse** — Proprietary technology (trademark) used to map and interrogate the immune synapse between T cells and their targets.
- **T-Ca (T-Cα)** — Proprietary technology (trademark) within T-Cypher Bio's computational and wet-lab toolkit.
- **TCR therapeutics pipeline** — Pipeline of immune engagers against novel targets across solid tumours and selected autoimmune / inflammatory diseases.

## Achievements

- Spun out of Orbit Discovery in 2021 as a standalone TCR therapeutics company.
- Built the D-Cypher integrated platform to overcome long-standing TCR discovery bottlenecks.
- Developed a functional bead-display approach that avoids T cell cloning and soluble-TCR generation.
- Secured founding backing from Oxford Science Enterprises and a syndicate of specialist investors.
- Reported to have raised roughly $24.3M across investors including Medicxi, LifeArc Ventures and Future Planet Capital.

## Latest updates

- **2021-02** — T-Cypher Bio launches, separating from Orbit Discovery to build a pipeline of TCR therapeutics for solid tumours and other indications.
- **2025-10** — Company website refreshed, highlighting T-Synapse and T-Ca proprietary technologies and a pipeline of immune engagers across cancer and autoimmune disease.

## Links

- Website: https://tcypherbio.com
- LinkedIn: https://uk.linkedin.com/company/t-cypher-bio

---

Profile page: https://yespress.io/t-cypher-bio
Published by YesPress — https://yespress.io
Last updated: 2026-07-02